Nasdaq Lenz News Today

LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) is one of 290 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare LENZ Therapeutics to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Earnings & Valuation […]

LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) Director Ra Capital Management, L.P. purchased 998,009 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was acquired at an average cost of $15.03 per share, for a total transaction of $15,000,075.27. Following the completion of the acquisition, the director now […]